Jazz Pharmaceuticals JAZZ EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Jazz Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Jazz Pharmaceuticals’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's EBITDA margin?
- Jazz Pharmaceuticals (JAZZ) reported EBITDA margin of -10.9% in Q3 2025.
- How has Jazz Pharmaceuticals's EBITDA margin changed year-over-year?
- Jazz Pharmaceuticals's EBITDA margin decreased by 164.1% year-over-year, from 17% to -10.9%.
- What is the long-term trend for Jazz Pharmaceuticals's EBITDA margin?
- Over 4 years (2020 to 2024), Jazz Pharmaceuticals's EBITDA margin has grown at a 2.3% compound annual growth rate (CAGR), from 16.8% to 18.4%.
- What does EBITDA margin mean?
- Operating cash profitability per sales dollar, before interest, taxes, and non-cash charges.
- How do you interpret EBITDA margin?
- Useful for comparing operating profitability across firms with different depreciation policies and leverage. High EBITDA margin alongside heavy capex can still mean weak free cash flow — pair it with FCF margin.
- How does EBITDA margin compare across companies?
- Widely used to compare capital-intensive businesses on a like-for-like basis. Less meaningful for banks and insurers.